The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | Linking the diagnosis-to-treatment interval with ctDNA
Ash Alizadeh, MD, PhD, Stanford Comprehensive Cancer Center, Stanford, CA, discusses the connection between the diagnosis-to-treatment interval (DTI) and circulating tumor DNA (ctDNA) levels in diffuse large B-Cell lymphoma (DLBCL). A shorter DTI has been previously associated with worse patient outcomes. In an analysis of patients receiving standard care and in the Phase III PETAL trial (NCT00554164), a shorter DTI and high ctDNA levels accurately represented baseline tumor burden. Measuring ctDNA levels can consequently be used in a pre-clinical setting by effectively grouping patients in clinical trials. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
